S-1/A: Caring Brands Files S-1/A for Nasdaq Uplisting & Public Offering

Caring Brands Inc. is seeking to raise $4 million through a public offering and list on Nasdaq, while addressing significant operating losses and a going concern warning.

Summary

• Caring Brands Inc. is a wellness consumer products company offering OTC and cosmetic products for hair loss, eczema, psoriasis, vitiligo, and jellyfish sting protection.
• The company is filing an S-1/A registration statement for a public offering of 1,000,000 shares of common stock at $4.00 per share, aiming to raise $3.2 million in net proceeds.
• Proceeds from the offering are primarily allocated to product development ($1.9 million), legal & compliance ($100,000), related party loan repayment ($75,000), general & administrative expenses ($250,000), and general working capital ($875,000).
• The company plans to list its common stock on The Nasdaq Capital Market under the symbol CABR, contingent on approval, and will cease trading on OTCQB.
• A concurrent resale prospectus registers 2,610,000 shares for selling stockholders, including 2,110,000 shares issuable from warrants and 500,000 shares held by a shareholder.
• The company has a limited operating history and has incurred significant net losses: $1,199,353 for the six months ended June 30, 2025, and $1,517,431 for the year ended December 31, 2024 (pro forma).
• A 'going concern' warning is noted due to recurring losses and negative cash flows, with future operations contingent on successful capital raises.
• Photocil, for vitiligo and psoriasis, was removed from the U.S. market in February 2023 due to insufficient sales and lack of a dedicated sales/marketing team; a relaunch is targeted for 2026.
• Hair Enzyme Booster (JW-700) was launched on Amazon in October 2024 and NOVODX in December 2024, but sales have been minimal during the initial soft launch.
• CB-101 (eczema treatment) is undergoing reformulation, with a target online availability in the U.S. in Q2 2026.
• NoStingz (sunscreen/jellyfish sting protection) is also undergoing reformulation, with no established commercial launch timeline.
• The company has licensing agreements for Hair Enzyme Booster and Photocil in India (with Cosmofix and San Pellegrino Cosmetics) and Japan (with Taisho Pharmaceutical Co., Ltd.).
• An exclusive non-exclusive license agreement with related party NOVODX Corporation grants rights to research, market, and sell the GoldNTM Ebola Rapid Test.
• Safety Shot Inc., the former parent company, owns approximately 18.2% of Caring Brands' outstanding common stock.
• The company has 13,736,925 shares of common stock outstanding as of September 5, 2025, which will increase to 14,736,925 after the public offering (excluding over-allotment).
• The company's net tangible book value as of June 30, 2025, was negative ($0.01) per share, with new investors facing an immediate dilution of $3.77 per share at the $4.00 offering price.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses and a 'going concern' warning. While it has a diverse product pipeline and market opportunities, most products are in early commercialization or reformulation stages, and past U.S. launches have failed. The public offering and Nasdaq uplisting are critical for survival and future development, but come with substantial dilution and market risks.

Positives

• The company is pursuing a Nasdaq listing, which could improve market visibility and access to capital.
• Products like Photocil and Hair Enzyme Booster have undergone clinical trials demonstrating efficacy for their intended uses.
• Hair Enzyme Booster has 2 granted and 5 pending patents, and is licensed to Taisho, Japan's leading minoxidil product seller, with commercial launch expected in 2025.
• Photocil has published clinical trial results in reputable journals, showing significant efficacy in treating vitiligo and psoriasis.
• CB-101 for eczema showed promising results in prior clinical studies (JW-100 formulation), clearing or reducing eczema in 2 weeks.
• NoStingz demonstrated promising initial results in a small preliminary trial for reducing jellyfish sting severity.
• The global phototherapy treatment market is projected to grow from ~$1.9 billion in 2023 to ~$3.23 billion by 2033 (CAGR 5.2%), with India's market expanding faster at ~7.8%.
• The global psoriasis treatment market was worth ~$34 billion in 2023 and is expected to reach ~$54-67 billion by 2030.
• The global vitiligo treatment market was valued at ~$538.90 million in 2024 and is projected to grow to ~$807.70 million by 2034 (CAGR 4.60%).
• The minoxidil market was valued at $1.5 billion in 2022 and is expected to grow to $2.5 billion by 2032.
• The global eczema treatment market was valued at $14 billion in 2022.
• Manufacturing partners (Stella Industries Ltd. in India, DCR Labs in Florida) are compliant with cGMP regulations and ISO-9001 certified, ensuring product quality and stability.
• The company has an exclusive non-exclusive license for the GoldNTM Ebola Rapid Test, which boasts high sensitivity and specificity, meeting WHO ASSURED criteria.

Negatives

• The company has a limited operating history and has incurred significant recurring losses, raising substantial doubt about its ability to continue as a going concern.
• Revenue has been nominal, with $3,056 for the six months ended June 30, 2025, and $465 for the period April 24 to December 31, 2024.
• Net losses were $1,199,353 for the six months ended June 30, 2025, and $862,791 for the period April 24 to December 31, 2024.
• Cash and cash equivalents were only $73,893 as of June 30, 2025.
• Photocil was removed from the U.S. market in February 2023 due to insufficient sales and lack of a dedicated sales and marketing team.
• Hair Enzyme Booster (JW-700) sales have been minimal during its initial soft launch period on Amazon and NOVODX.
• CB-101 development is on hold pending reformulation, and NoStingz reformulation is also ongoing with no set commercial launch timeline.
• The company faces intense competition from larger, more established companies with greater resources and brand recognition.
• The separation from Safety Shot Inc. may lead to increased costs and susceptibility to market fluctuations, and the terms of the separation agreement may be less favorable than if negotiated with unaffiliated third parties.
• Some directors and executive officers hold Safety Shot common stock, potentially creating conflicts of interest.
• The company's products are regulated as cosmetics or OTC products, and any disagreement by the FDA could require reformulation, pre-market approval, or lead to enforcement actions.
• The success of the Ebola Rapid Test license is contingent on NOVODX obtaining 510K or EUA approval, and patent applications are still in process.
• The company's ability to obtain additional funding is uncertain and failure to do so could force it to curtail or cease operations.
• New investors in the public offering will experience significant immediate dilution of $3.77 per share.
• The company does not intend to pay dividends for the foreseeable future.

Risks

• Inability to achieve expected benefits from the separation from Safety Shot Inc.
• Increased costs and operational challenges as a standalone public company after the separation.
• Conflicts of interest due to some directors and executive officers holding Safety Shot common stock or positions.
• Limited operating history makes business prospects difficult to evaluate and forecasts unreliable.
• Inadequate capital to fund business operations, with no assurance of future financing availability on acceptable terms.
• Inability to successfully compete against companies with substantially greater resources and brand recognition.
• Product liability and related risks from the sale of products, potentially leading to significant insurance and loss expenses.
• Inability to keep up with rapid technological changes, potentially rendering products obsolete.
• Adverse publicity associated with products or ingredients could negatively affect sales and revenue.
• Products may not meet health and safety standards or could become contaminated, leading to recalls and liability claims.
• Lack of FDA approval for disease treatment claims for current products, and potential delays/rejections for future product candidates requiring such approval.
• Serious adverse or undesirable side effects identified during product development could lead to abandonment or limitation of commercialization.
• Delays or difficulties in enrolling subjects for clinical trials could delay or prevent regulatory approvals.
• Inability to manufacture products in sufficient quantities or at defined quality specifications, or obtain regulatory approvals for manufacturing facilities.
• Uncertainty regarding the adequacy of product liability insurance or its future affordability/availability.
• Market opportunities for current and future drug candidates may be smaller than anticipated.
• Inability to establish effective relationships with licensees or collaborators for sales, marketing, and distribution.
• Regulatory classification of products as cosmetics or OTC may be challenged by the FDA, requiring costly changes or leading to enforcement actions.
• Lack of market acceptance by physicians, payers, and patients for OTC/Cosmetic product candidates.
• Exposure to federal and state fraud and abuse laws if product candidates receive FDA approval and are commercialized.
• Natural disasters and other uncontrollable events could adversely affect operations.
• Failure to meet product development and commercialization milestones.
• Inherent risks associated with international market operations, including macroeconomic conditions, foreign currency exchange rates, political instability, and regulatory requirements.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies.
• Difficulty in evaluating current and future business prospects due to potential rapid growth and entry into new markets.
• Changes in tax laws and unanticipated tax liabilities could adversely affect the effective income tax rate.
• Substantial costs from litigation or other proceedings relating to intellectual property rights.
• Inability to adequately protect intellectual property could reduce product value and profitability.
• Expiration of intellectual property protection and reliance on unpublished know-how held by key individuals.
• Reduced disclosure requirements as an emerging growth company may make common stock less attractive to investors.
• Strain on resources and management distraction due to public company requirements.
• Limited management experience in managing a public company, potentially leading to additional expenses.
• Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.
• Significant percentage of voting securities held by certain stockholders could reduce minority stockholders' ability to effect corporate actions.
• Inaccurate or unfavorable research by securities or industry analysts could cause stock price decline.
• Issuance of additional common or preferred stock may cause common stock price to decline.
• Common stock may become subject to SEC's penny stock rules, adversely affecting trading activity.
• Inability to implement and maintain effective internal control over financial reporting.
• Concurrent resale of shares by selling stockholders could adversely impact market price, liquidity, and demand for common stock.
• Uncertainty of an active, liquid, and orderly trading market for common stock.
• Inability to satisfy Nasdaq listing requirements or maintain listing.
• Investing in the company is highly speculative and could result in the entire loss of investment.
• Anti-takeover provisions in charter and bylaws may prevent or frustrate attempts to change the board or management.

Future Outlook

The company aims to expand its product line and market presence, with targeted U.S. relaunches for Photocil and CB-101 in 2026. It plans to invest significantly in manufacturing setup, marketing campaigns, and clinical testing for its key products using proceeds from the public offering. The company is also evaluating market opportunities for the Ebola Rapid Test and exploring additional sub-licensing opportunities for Photocil and Hair Enzyme Booster in various international markets. Long-term growth strategy includes seeking acquisition opportunities in branded consumer products that do not require additional FDA approval.

Management Comments

• Management believes that phototherapy treatments, used for conditions such as psoriasis and vitiligo, are set for substantial growth globally.
• Management believes that Psoriasis treatment with Photocil may only address a very small fraction of the market in the US and India.
• Management believes India presents a potential opportunity for market expansion for vitiligo treatments.
• Management believes that Vitiligo treatment with Photocil is expected to address only a very small fraction of the total global market.
• Management believes that the foregoing liquidated damages provision represents reasonable compensation for the loss which would be incurred by the Lender due to any such breach (regarding timely share delivery).

Industry Context

Caring Brands operates in the highly competitive wellness consumer products industry, specifically targeting segments like hair loss, eczema, psoriasis, vitiligo, and sun protection. The markets for these conditions are substantial and projected to grow, driven by increasing prevalence of skin disorders and demand for effective treatments. The company differentiates itself through products with unique mechanisms of action and clinical benefits, aiming to compete against larger pharmaceutical and cosmetic companies. Its strategy includes leveraging e-commerce and exploring international licensing, particularly in high-growth regions like India and Asia Pacific. The entry into rapid diagnostic tests for Ebola with NOVODX represents a diversification into the medical diagnostics sector, addressing critical public health needs.

Comparison to Industry Standards

• Photocil's narrow-band UV filter technology is presented as a differentiated approach compared to conventional UV blockers found in most sunscreens, offering therapeutic properties for psoriasis and vitiligo.
• Hair Enzyme Booster (JW-700) is designed to enhance the efficacy of minoxidil, an FDA-approved hair loss treatment, by increasing sulfotransferase enzymes. This positions it as a complementary product in the $1.5 billion (2022) minoxidil market, rather than a standalone treatment.
• CB-101 (eczema treatment) aims to be an OTC product under a USP monograph, utilizing aspartame and colloidal oatmeal. Previous formulation (JW-100) showed potential superiority to existing prescription drugs in clinical studies, targeting a $14 billion (2022) global eczema market where 86% of Americans are dissatisfied with current treatments.
• NoStingz is being reformulated as a sunscreen with dual protection against UV rays and jellyfish stings, a niche offering in the broader sunscreen market.
• The GoldNTM Ebola Rapid Test, licensed from NOVODX, claims to be at least 1,000 times more sensitive than available commercial RDTs, achieving over 98% accuracy comparable to some PCR tests, and meets WHO ASSURED criteria, positioning it as a significant advancement in Ebola diagnostics.

Management Changes

Corporate Governance

Legal Proceedings

• Not a party to any pending legal proceeding, nor is property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of the business.
• None of the directors, officers or affiliates are involved in a proceeding adverse to the business or have a material interest adverse to the business.

Related Party Transactions

• Safety Shot Inc. (former parent company) owns approximately 18.2% of outstanding common stock.
• Safety Shot Inc. waived an outstanding balance of $275,876 at September 24, 2024, treating it as additional paid-in capital during the separation.
• Short-term loan agreement for $50,000 entered on June 5, 2025, with CEO Dr. Glynn Wilson, due November 5, 2025, at 8% interest.
• Short-term loan agreement for $25,000 entered on July 24, 2025, with Chairman of the Board Mr. Brian John, due December 24, 2025, at 8% interest.
• NOVODX Corporation, a related party (CEO Nancy Torres was a former director), participated in a private placement, acquiring 500,000 shares for $500,000 cash in May 2024.
• The company invested $500,000 in NOVODX's private placement for 25,134 shares of NOVODX common stock in June 2024.
• Research Collaboration and Non-Exclusive License Agreement with NOVODX Corporation (amended July 22, 2024) for the Ebola Rapid Test, involving issuance of 3,000,000 shares of restricted common stock, a $100,000 initial payment (due upon S-1 effectiveness), milestone payments ($1M upon 510K/EUA approval, $500K at $5M annual net sales), and royalties (5% under $500M net sales, 3% over $500M net sales).
• Consulting agreement with Genesis One Holdings, LLC (June 20, 2025) for business planning and investor relations services, including a fixed cash fee and stock compensation of 200,000 shares (issued September 5, 2025).
• Service agreement with Greentree Financial Group, Inc. (August 4, 2025) for professional accounting operations services, in exchange for a fixed fee of $30,000 and issuance of 200,000 shares of common stock (issued September 5, 2025).
• Convertible promissory note for $200,000 entered on August 6, 2025, with Greentree Financial Group, Inc., at 10% annual interest, convertible at $2.00 per share or latest sale price (whichever is less), including a 10% original issue discount and a one-time grant of 25,000 shares of common stock, plus 200,000 warrants to purchase shares at $4.00 per share (expiring August 6, 2030).

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience significant dilution from the public offering and potential future capital raises. The 'going concern' warning indicates a high risk of investment loss. The Nasdaq uplisting could improve liquidity and visibility, but there's no guarantee of an active trading market or sustained stock price.
• **Employees:** The company has four full-time employees, including key executives. Their compensation includes base salaries, potential bonuses, and stock/option awards, aligning their interests with company performance. However, the company's financial instability poses a risk to job security and future compensation.
• **Customers:** The company's focus on clinically-backed OTC and cosmetic products aims to provide effective solutions for various health and wellness needs. However, past product removals from the U.S. market due to insufficient sales suggest challenges in meeting customer demand or marketing effectively.
• **Suppliers/Manufacturers:** The company relies on third-party manufacturers (Stella Industries, DCR Labs) and raw material suppliers. Maintaining strong relationships and ensuring consistent supply is crucial for product development and commercialization. Financial instability could impact timely payments to suppliers.
• **Creditors:** Related party loans and a convertible promissory note indicate reliance on debt financing. The 'going concern' warning highlights the risk to creditors regarding repayment of outstanding balances.

Next Steps

• Complete the public offering of 1,000,000 shares of common stock.
• Obtain approval for listing common stock on The Nasdaq Capital Market under the symbol CABR.
• Initiate preparation for scaling-up Photocil manufacturing between Q3 and Q4 2025.
• Initiate FDA registration process for Photocil by Q4 2025.
• Develop a marketing campaign, U.S. market relaunch, and e-commerce platform integration for Photocil between Q4 2025 and Q1 2026.
• Initiate reformulation process for CB-101 in Q4 2025, with completion by Q1 2026.
• Initiate production run and clinical testing for CB-101 by Q2 2026.
• Develop marketing materials campaign, U.S. market relaunch, and e-commerce platform integration for CB-101 by Q3 2026.
• Complete reformulation and initiate stability testing for NoStingz by Q4 2025.
• Complete stability testing and initiate FDA registration process for NoStingz by Q1 2026.
• Initiate production run and finalize launch timeline for NoStingz between Q4 2025 and Q1 2026.
• Evaluate market opportunities for the Ebola Rapid Test and determine development timeline and costs.
• Expand sales and marketing team for Hair Enzyme Booster (JW-700) and other products.
• Explore additional sub-licensing opportunities for Photocil and Hair Enzyme Booster in Nepal, Bangladesh, Sri Lanka, Vietnam, Philippines, Malaysia, Cambodia, Laos, Indonesia, UAE, Egypt, Algeria, Tunisia, Congo, Nigeria, Kenya, Thailand, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, and Saudi Arabia.
• Continue preliminary discussions regarding potential licensing opportunities in Europe and South America.
• Seek acquisition opportunities in the branded consumer products space, including OTC/cosmetic therapeutic brands and skin care brands.

Key Dates

Recommendation

The company presents a high-risk investment profile. It has a limited operating history, nominal revenue, and significant recurring net losses, leading to a 'going concern' warning from its auditors. While the product pipeline addresses large markets, past U.S. commercialization efforts for key products like Photocil and NoStingz have failed due to insufficient sales and lack of marketing. The current public offering will result in substantial dilution for new investors, and there's no guarantee of a successful Nasdaq uplisting or sustained market price. The company's ability to secure additional financing is uncertain, and failure to do so could lead to cessation of operations. Given the severe financial distress, high operational risks, and significant dilution, a seasoned investor would likely recommend selling or avoiding this stock.

Keywords

Wellness Consumer Products, OTC Products, Cosmetic Products, Hair Loss Treatment, Eczema Treatment, Psoriasis Treatment, Vitiligo Solution, Jellyfish Sting Protection, Minoxidil Booster, Photocil, CB-101, NoStingz, Ebola Rapid Test, SEC Filing, S-1/A, Public Offering, Nasdaq Uplisting, Biotechnology, Pharmaceutical, Skin Care, Hair Care, Medical Diagnostics, Corporate Governance, Risk Factors, Capital Raise, Going Concern